HC Wainwright & Co. Reiterates Buy on Lyra Therapeutics, Maintains $12 Price Target

Benzinga · 03/22 10:40
HC Wainwright & Co. analyst Matthew Caufield reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Buy and maintains $12 price target.